Monoclonal antibody

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 12, 2023
CLL, Vaccine, Chronic lymphocytic leukemia, SARS-CoV-2, Public, Biotechnology, COVID-19, Smallpox, Head, Breast, Infection, Prostate, Messenger, Monoclonal antibody, Hematological Cancer Research Investment and Education Act, Labs, Patient, Cancer, Immunodeficiency, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NIH, Conference, Food, Pfizer, MVA, Pharmaceutical industry, Moderna

ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 11. A webcast replay of Mr. Dodd’s presentation can be viewed here.

Key Points: 
  • ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, presented a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 11.
  • A webcast replay of Mr. Dodd’s presentation can be viewed here .
  • During his presentation, Mr. Dodd reviewed the Company’s four ongoing Phase 2 clinical trials:
    As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy).
  • As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine.

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

Retrieved on: 
Monday, September 11, 2023
CLL, Vaccine, Volunteering, Antigen, GeoVax, Chronic lymphocytic leukemia, SARS-CoV-2, Biotechnology, COVID-19, Clinical trial, Infection, Messenger, Monoclonal antibody, Hematological Cancer Research Investment and Education Act, COVID-19 vaccine, Patient, Risk, Immune system, Cancer, Universal, Immunodeficiency, FDA, Capsid, Pfizer, MVA

ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has met the enrollment target for its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine (ClinicalTrials.gov Identifier: NCT04639466).

Key Points: 
  • The immunological responses measured throughout the study will include both the level of neutralizing antibodies against SARS-CoV-2 variants of concern and specific T cell responses.
  • GEO-CM04S1 is a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose.
  • The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of COVID-19.
  • These data support the progression of the Phase 2 clinical study, which includes a direct comparison to currently approved mRNA vaccines.

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

Retrieved on: 
Wednesday, September 13, 2023
Monoclonal antibody, ADC, Spacecraft, KOSDAQ, Partnership, Acquisition, Research, Doctor of Philosophy, Fine chemical

ABL Bio will be responsible for the research, development, and commercialization of any bispecific ADCs developed under the agreement.

Key Points: 
  • ABL Bio will be responsible for the research, development, and commercialization of any bispecific ADCs developed under the agreement.
  • Following the recent acquisition of Synaffix by Lonza, ABL Bio considers Lonza as a potential partner for clinical production of the antibody to be used in the first program, underscoring the strong and immediate post-merger synergies.
  • Peter van de Sande, Head of Synaffix, said: "Under our collaboration with ABL Bio, we will focus on the discovery and development of cutting-edge bispecific ADCs.
  • With close collaboration between ABL Bio and Synaffix, I'm confident that we will achieve remarkable results in the ADC field."

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

Retrieved on: 
Wednesday, September 13, 2023
Monoclonal antibody, ADC, Spacecraft, KOSDAQ, Partnership, Acquisition, Research, Doctor of Philosophy, Fine chemical

ABL Bio will be responsible for the research, development, and commercialization of any bispecific ADCs developed under the agreement.

Key Points: 
  • ABL Bio will be responsible for the research, development, and commercialization of any bispecific ADCs developed under the agreement.
  • Following the recent acquisition of Synaffix by Lonza, ABL Bio considers Lonza as a potential partner for clinical production of the antibody to be used in the first program, underscoring the strong and immediate post-merger synergies.
  • Peter van de Sande, Head of Synaffix, said: "Under our collaboration with ABL Bio, we will focus on the discovery and development of cutting-edge bispecific ADCs.
  • With close collaboration between ABL Bio and Synaffix, I'm confident that we will achieve remarkable results in the ADC field."

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3

Retrieved on: 
Thursday, September 7, 2023
Carcinoma, CD47, Macrophage, ADCC, ODD, Glomus tumor, Monoclonal antibody, NEPC, Pharmacokinetics, NK, Research, APC, SCLC, DLL3, Patient, SAN, ADCP, FDA, Therapy, Safety, Disease, Pharmaceutical industry

SAN DIEGO, Sept. 7, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the Phase 1 clinical study (NCT05652686) of PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47 for the treatment of small cell lung cancer and other neuroendocrine tumors. PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.

Key Points: 
  • PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.
  • The anti-CD47 arm of PT217 is differentiated and has demonstrated minimum binding to human red blood cells while maintaining strong binding activity to CD47 on tumor cells.
  • "Small cell lung cancer is one of the most devastating and aggressive solid tumor cancers with patients lacking effective therapies to treat their disease.
  • PT217 is a product of Phanes' ingenious innovation in creative design of both novel therapeutic approaches and practical technologies," said Dr. Ming Wang, Founder and CEO of Phanes.

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

Retrieved on: 
Tuesday, September 5, 2023
Bispecific monoclonal antibody, Monoclonal antibody, Gilead Sciences, Therapy, CD3, Cancer, Macrogen, Research, Gilead, GILD, CD123, Pharmaceutical industry, MD

This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.

Key Points: 
  • This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.
  • Under the October 2022 agreement, MacroGenics will receive $15 million related to the nomination of a bispecific research program to be conducted by MacroGenics and funded by Gilead.
  • Pursuant to this agreement, which covers MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and up to two additional bispecific research programs, MacroGenics remains eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones.
  • MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Retrieved on: 
Monday, August 14, 2023
Monoclonal antibody, Growth factor, CD3, Neoplasm, CCR4, Head, Breast, CCR8, Antibody, Doctor of Philosophy, Lung, Animal, Cancer, SAN, EGFR, Carcinoma, IND, Vaccine, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced positive pre-clinical in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage.

Key Points: 
  • In preclinical studies, iBio’s anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.
  • iBio developed the antibody using its patented AI epitope steering technology.
  • By focusing solely on the tumor-specific variant, iBio aims to reduce potential side effects.
  • In addition to the anti-EGFR program, iBio’s CCR8 antibody has proven effective in a mouse model for colon cancer.

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Retrieved on: 
Thursday, August 10, 2023
Idiopathic disease, Melanoma, Idiopathic pulmonary fibrosis, Experiment, Doctor of Philosophy, Development, Patent, MD, Patient, Hermansky–Pudlak syndrome, Breast cancer, Brain, Prostate cancer, Malaria, Therapy, Climate, NASH, RI, Skin cancer, Research, Glioblastoma, Pulmonary fibrosis, Fatty liver disease, Response evaluation criteria in solid tumors, IPF, Death, Alcoholic liver disease, Monoclonal antibody, Kidney cancer, Lung cancer, Extension, Treatment of lung cancer, Messenger, Fibrosis, Science, Biomedicine, Cancer, Parasitism, Ovarian cancer, CHI3L1, Q&A, Lung, HPS, World Health Organization, Scleroderma, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Ocean Biomedical

Providence, RI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, shared today an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers.

Key Points: 
  • In addition to the multi-pronged cancer program, the Company is advancing a novel malaria vaccine candidate and a companion malaria drug program.
  • The Company is also working to advance a much-needed pulmonary fibrosis treatment candidate to raise the standard of care available to patients with pulmonary fibrosis.
  • “Our team is simultaneously targeting several major cancer pathways,” said Dr. Jack A. Elias, a Scientific Co-founder of Ocean Biomedical.
  • Similarly, malaria and the cancers we are targeting are not adequately addressed by the current therapeutics because of efficacy or side effect shortcomings.

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Monoclonal antibody, US Food Sovereignty Alliance, Clinical trial, OS, Trae tha Truth, Quality of life, TKI, NSCLC, Immunotherapy, Lung cancer, PFS, ASCO, VEGF, Hair, American Society of Clinical Oncology, Patient, Investment, EGFR, Anemia, Annual general meeting, SMMT, Webcast, Knowledge, PD-1, FDA, Phase, Collaboration, Society, ORR, Pharmaceutical industry, Road, Security (finance), Cryptocurrency, Rare-earth element

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.
  • Summit intends to dose patients in the HARMONi-3 trial during the second half of 2023.
  • Net loss for the three and six months ended June 30, 2023 was $14.7 million and $557.1 million, respectively.
  • Operating cash outflow for the six months ended June 30, 2023 and 2022 was $42.4 million and $38.2 million, respectively.